Drug Repurposing News and Research

RSS

14 existing drugs identified as SARS-CoV-2 main protease inhibitors

Now, a new study published on the preprint server bioRxiv in August 2020 reports on the identification of 14 compounds that can inhibit the key viral enzyme called the Main Protease (MPro) at micromolar concentrations.

1 Sep 2020

Cat antiviral that inhibits SARS-CoV-2 fast-tracked for human clinical trials

Now, a team of researchers at the University of Alberta in Canada has identified viral inhibitors that they claim are potential candidates as a treatment for COVID-19. The team is set to launch clinical trials of the drug that is used as a treatment for a type of coronavirus in cats.

31 Aug 2020

Scientists describe known approaches for treatment of SARS-CoV-2 infection

Researchers from Sechenov University together with Russian and Iranian colleagues described currently known approaches to the treatment of SARS-CoV-2 infection.

29 Aug 2020

Bioinsider presents ‘Therapeutic Pipeline for COVID-19’ virtual meeting on September 17, 2020

Bioinsider, has opened registration for its upcoming virtual meeting ‘Therapeutic Pipeline for COVID-19’ on September 17, 2020.

From Twist Bioscience 24 Aug 2020

AI can expedite drug repurposing process for finding COVID-19 therapies, says GlobalData

Out of all the different approaches available to find new therapies to treat COVID-19, drug repurposing is one of the fastest and safest methods, as the drugs are already being used to treat other conditions therefore leading to fewer chances of adverse reactions.

21 Aug 2020

CARE consortium launches to accelerate drug discovery and development for COVID-19

CARE a new consortium supported by the Innovative Medicines Initiative public-private partnership announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19.

19 Aug 2020

Machine learning helps detect new potential drugs to treat COVID-19

Scientists at the University of California, Riverside, have used machine learning to identify hundreds of new potential drugs that could help treat COVID-19, the disease caused by the novel coronavirus, or SARS-CoV-2.

12 Aug 2020

Focusing on human enzymes and not SARS-CoV-2 could help treat COVID-19

Now, breakthrough research into malaria suggests targeting enzymes from the human host, rather than from the pathogen itself. The new research could pave the way for effective treatments for a wide range of infectious diseases, including the coronavirus disease (COVID-19).

11 Aug 2020

Artificial intelligence can increase effectiveness of drug repurposing for psychiatric disorders

Artificial intelligence can increase the effectiveness of drug repositioning or repurposing research, according to a study published in Translational Psychiatry.

3 Aug 2020

An important SARS-CoV-2 enzyme is responsible for low in vivo antiviral efficacy of hydroxychloroquine

Researchers have shown that hydroxychloroquine interferes with only one redundant pathway that activates the SARS-CoV-2 spike protein.

24 Jul 2020

Sanford Burnham Prebys receives CIRM award to advance promising drug candidates for COVID-19

Sanford Burnham Prebys Medical Discovery Institute has received an award from the California Institute for Regenerative Medicine to advance promising drug candidates for COVID-19.

21 Jul 2020

Study identifies three novel broad-spectrum SARS-CoV-2 cell entry inhibitors

Researchers from the National Institutes of Health (NIH) and Cornell University in the U.S. just described several new inhibitors of human coronavirus spike proteins by screening a library of approved drugs with SARS-S and MERS-S pseudotyped particle entry assays. Their exciting findings are currently available on the bioRxiv preprint server.

13 Jul 2020

Use of whole blood transcriptomes may improve COVID-19 diagnosis and treatment

In a new paper published on the preprint server medRxiv*, a multinational group of researchers provide the first evidence for the use of whole blood transcriptomics to distinguish coronavirus disease (COVID-19) from other infections, and also to monitor and potentially predict disease outcomes.

9 Jul 2020

New platform prioritizes synergistic drug combinations against SARS-CoV-2

Researchers in the U.S. have used a new web-based platform to help identify synergistic and antagonistic drug combinations and their underlying mechanisms of action in the context of coronavirus disease 2019 (COVID-19).

2 Jul 2020

Repurposed drug for acute lung injury in COVID-19

Now, a new study addresses the possible use of an FDA-approved monoclonal antibody, called fostamatinib, a spleen tyrosine kinase inhibitor (SYK), to reduce the levels of mucin-1, a molecule associated with acute lung injury and acute respiratory distress syndrome (ARDS). People who have severe COVID-19 disease may develop ARDS.

2 Jul 2020

Researchers perform first X-ray measurements on SARS-CoV-2 main protease

A team of researchers at the Department of Energy's Oak Ridge and Argonne national laboratories has performed the first room-temperature X-ray measurements on the SARS-CoV-2 main protease -- the enzyme that enables the virus to reproduce.

26 Jun 2020

C-Path announces launch of CURE Drug Repurposing Collaboratory

As millions of patients struggle with diseases that lack adequate treatments, there is a critical need to understand how existing drugs can be used in new ways to improve clinical outcomes.

23 Jun 2020

Steroidal drugs subvert SARS-CoV-2 interaction with ACE2 receptors

A new study by Italian researchers and published online on the preprint server bioRxiv* in June 2020 reports the ability of several existing steroidal drugs to reduce the binding of the SARS-CoV-2 to the ACE2 receptor. This could help define newer strategies using viral entry blockers to reduce viral load.

14 Jun 2020

Does COVID-19 injure the placenta of pregnant women?

News-Medical speaks to Dr. Jeffery Goldstein about whether COVID-19 is damaging the placentas of pregnant women and what women can do to protect themselves.

12 Jun 2020

Research shows potential new therapeutic strategy for slowing down Huntington's disease

Scientists have described a potential new therapeutic strategy for slowing down early-stage Huntington's disease in a new study published today in eLife.

9 Jun 2020